189 related articles for article (PubMed ID: 33065408)
1. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
Shaw JR; Kumar V; Mallick R; Carrier M; Ilich A; Key NS; Wells P
Thromb Res; 2020 Dec; 196():437-443. PubMed ID: 33065408
[TBL] [Abstract][Full Text] [Related]
2. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
[TBL] [Abstract][Full Text] [Related]
3. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
Li S; Gao P; Qiu J; He X; Mao Y
J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.
Overvad TF; Ording AG; Nielsen PB; Skjøth F; Albertsen IE; Noble S; Vistisen AK; Gade IL; Severinsen MT; Piazza G; Larsen TB
Blood Adv; 2022 May; 6(10):2967-2976. PubMed ID: 35045569
[TBL] [Abstract][Full Text] [Related]
5. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
van Es N; Ventresca M; Di Nisio M; Zhou Q; Noble S; Crowther M; Briel M; Garcia D; Lyman GH; Macbeth F; Griffiths G; Iorio A; Mbuagbaw L; Neumann I; Brozek J; Guyatt G; Streiff MB; Baldeh T; Florez ID; Gurunlu Alma O; Agnelli G; Ageno W; Marcucci M; Bozas G; Zulian G; Maraveyas A; Lebeau B; Lecumberri R; Sideras K; Loprinzi C; McBane R; Pelzer U; Riess H; Solh Z; Perry J; Kahale LA; Bossuyt PM; Klerk C; Büller HR; Akl EA; Schünemann HJ;
J Thromb Haemost; 2020 Aug; 18(8):1940-1951. PubMed ID: 32336010
[TBL] [Abstract][Full Text] [Related]
6. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
7. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
9. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
10. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C; Giaccherini C; Russo L; Bolognini S; Gamba S; Tartari CJ; Schieppati F; Ticozzi C; Vignoli A; Masci G; Sarmiento R; Spinelli D; Malighetti P; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Gasparini G; Minelli M; De Braud F; Santoro A; Labianca R; Marchetti M; Falanga A;
J Thromb Haemost; 2023 Jul; 21(7):1869-1881. PubMed ID: 37054917
[TBL] [Abstract][Full Text] [Related]
11. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
12. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.
Wang TF; Mallick R; Carrier M; Wells PS
Thromb Res; 2022 Mar; 211():85-87. PubMed ID: 35124234
[TBL] [Abstract][Full Text] [Related]
14. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
[TBL] [Abstract][Full Text] [Related]
15. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
16. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
17. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
18. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
Nishimura A; Ikeda Y
Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
[TBL] [Abstract][Full Text] [Related]
19. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
20. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]